Method of producing d-phenylalanyl-d-prolyl-l-arginine-aldehyde sulfate

专利摘要:
D-phenylalanyl-L-prolyl-L-arginine aldehyde sulfate, which is highly stable in aqueous solution, is described. A process for preparing the compound from D-phenylalanyl- L-propyl-L-argine aldehyde hemisulfate or D-phenylalanyl-L-prolyl-N<G>- carboxy-L-arginine aldehyde containing an acid-cleavable protecting group and its amino terminal, wherein the acid-cleavable amino terminal protecting group and optionally the N<G>-carboxy group is removed with 1 to 12 equivalents of 1 to 12 N sulfuric acid, and the resulting free tripeptide aldehyde sulfate isolated, is also described. D-phenylalanyl-L-prolyl-L-arginine aldehyde sulfate possesses anti- coagulant activity.
公开号:SU1442078A3
申请号:SU823374350
申请日:1982-01-13
公开日:1988-11-30
发明作者:Байюс Шандор；Селл Эржебет；Барабаш Ева；Багди Даниел
申请人:Рихтер Гедеон Ведьесети Дьяр Рт (Инопредприятие)；
IPC主号:

专利说明:

. (21) 3374350 / 23-04
(22) 13.0t.82
(31) 70/81
(32) 01/13/81
(33) neither
(46) 11/30/88. Bul No. 44
(71) Richter Gedeon Veseseti D'R RT
(neither)
(72) Shandor Bayus, Erzhebet Sell, Barabash and Daniel Bagdi (HII) S53) 547.964.4.07 (088.8)
p6) Ondetti MA and others. Design 6f specific inhibitors of angiotensin-converting: antibipertensiyfe - agent Science, v, 196, p.441, 1977.
Patent of Hungary No. 169870, class C 07 C 103/52, published. 1977.
(54) C110cb PREPARATION OF D-PHYLENAPANIP-b-prolIP-b-arginine aldehyde sulphate (57) medicine. The purpose of the invention is to create a new, more active and less toxic peptide. Its synthesis is carried out from the indicated aldehyde or its hemisulphate blocked by the weight group, which is deblocked by treatment with 8–12-fold equivalent amounts of 5–12 n. at 40-60 ° C for 10-20 minutes, followed by neutralization of the solution and the selection of the target product. Output 79% () t t8.1 (, in water), gross f-la C {., H3R, H4-Ng504 3N O-0.2 CaSO4, mol.m. 565.85. New peptide has good stability when stored in aqueous solutions. Thus, in comparison with the known salts of the indicated peptide-g and anti-thrombin activity, it lasts up to 180 days for 5 days at
toxicity LD 960/2000 mg / kg.
. five
4 tab.
i
four
4 :: u o
oo

s
This invention relates to a method for the production of B-phenylalanil-L-prolyl-b arginine aldehyde sulfate, a new biologically active compound that can be used in medicine.
The purpose of the invention is a method for producing new compounds in a number of low-toxic peptides with high antithrombogenic activity, which is retained for a long time when stored in aqueous solutions.
In the process, the purity of the products is monitored by chromatography on a thin layer of Silica gel G (Reanal, Budapest) in the following solvent systems:
Ethyl acetate-pyridine-acetic acid-water 480: 20: 6: 11;
Ethyl acetate-pyridine-acetic acid-water 60: 20: 6: 11;
Ethyl acetate-pyridine-acetic acid-water 30: 20: 6: 11.
 Example 1. O-phenylalanyl-b-prolyl-b-arginine aldehyde sulfate,
2.74 g (5 mmol) of tert-butoxycarbonyl-B-phenylalanyl-b-prolyl-b-arginine aldehyde hemisulfate is dissolved in 5 ml of water, and 5 ml of 10N is added with stirring. sulfuric acid, the mixture is heated to. The solution is stirred for 15 min at this temperature, then diluted with 25 ml of ice-cold water and the pH is set to 6.5 using solid calcium carbonate (approximately 2.25 g).
The calcium sulphate suspended in the precipitate is filtered and washed with 2 times 5 ml of ode. The filtrate is shaken twice with 10 ml of n-butanol, concentrated under reduced pressure to approximately 30 ml, preferably filtered and lyophilized. 2.25 g (79%) of the title compound are obtained, which contains 4.8% calcium sulphate. 35-0.40.
  (, in water).
Calculated,%: C 42.45, - H 6.77 N 14.85; SO 20.37; Ca 1.41; Н209.55
Gj, H ,, OjN ,. H, S04 3H O 0.2 CaS04 (mol.m. 565.85)
Found,%: C 42.2; H 6.9; N14.85 50419.8; Ca 1.3; 9.75.
Stage 1. Tert-butyloxy-carbonyl P-phenylalanyl-1.-prolyl-M-benzyloxy-carboni.p-). - pg and Nin-la Ktam,
0
,
five
. five
0 5
O
five
8.6 g (22 mmol) of tert-butyloxycarbonyl-N-benzyloxycarbonyl-L-arginine-lactam are suspended in 20 ml of ethyl acetate at 5 ° C. 40 ml of 4 M ethyl acetate-containing hydrochloric acid solution is added with stirring.
The reaction mixture is stirred for 30 minutes while cooling with ice water, then diluted with 100 ml of cooled ethyl acetate, the precipitated precipitate is filtered off, washed with ethyl acetate and dried over potassium hydroxide in a vacuum desiccator.
The N-benzyl oxycarbonyl-1-arginine lactam-chlorohydrate thus prepared is dissolved in 20 ml of dimethylformamide and after cooling to -10 ° C, 6.2 ml (44 mmol) of triethyl amine are added. The resulting suspension is added to the following anhydride.
7.25 g (20 mmol) of tert-butyloxycarbonip-D-phenylalanyl-L-proline and 2.22 ml (20 mmol) of N-methyl-morpholine are dissolved in 20 ml of dimethylformamide. The solution is cooled to -15 ° C and 2.64 ml (20 mmol) of chlorobolic acid isobutyl ester are added with stirring, then the above-mentioned dimethylformamide solution is added after 5 minutes. The reaction mixture is further stirred for an hour at and for one hour at 0 ° C. Then 30 ml of benzene are diluted, the precipitated salts are filtered off and washed twice with 10 ml of benzene each time. The benzene content is mixed with dimethylformamide solution and 50 ml of water and the phases are separated. The aqueous phase is extracted twice with 10 ml of benzene, then the combined benzene-containing solutions are washed successively three times with 30 ml of 10% sodium carbonate solution, 30 ml of water, and three times with 30 ml of 0.5N. sulfuric acid and twice with 30 ml of water; then, after drying over anhydrous sodium sulfate, it is evaporated under reduced pressure. The residue after evaporation is triturated with petroleum ether, filtered off, washed with petroleum ether and dried in air. 9.65 g (76%) of the title compound are obtained.
, 81 - 0.89,
Stage 2, Tert-butyloxy-carbonyl-D-phenylalanyl-L-polar-N -Renzyloxycarbonyl-b-arginine. Pddeg-id,
9.52 g (15 mmol) of the protected tripeptide-lactam (step 1) is dissolved in 45 ml of tetrahydrofuran at -20 ° C and with vigorous stirring a tetrahydrofuran-LiAlH4 solution containing 11.25 mmol of LiAlH4 (about 28 ml of 0.4 M solution). The course of the reduction is monitored by thin layer chromatography (F is the value of lacquer
tama is 0.71-0.77, and the aldehyde is 0.31-0.39) and, if necessary, a further amount of the hydride solution can be added. At the end of the reaction, the tetrahydrofuran solution was carefully acidified with 0.5N. sulfuric acid before, then diluted with water so that the substance does not precipitate (approximately 100 ml). Then it is extracted twice with 30 ml of hexane. The aqueous tetrahydrofuran solution was shaken three times with 75 ml of methylene chloride, then the combined methylene chloride solutions were washed three times with 10 ml of 10% sodium carbonate solution and twice with 10 ml of water. Thereafter, the methylene chloride-containing solution is dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue after evaporation is dissolved in 50 ml of benzene, and the solution is again evaporated under reduced pressure. The dissolution in benzene and evaporation are repeated one more time. The thus obtained residue after evaporation is triturated with diethyl ether, filtered off, washed with diethyl ether and air dried. Get 6.9 g (72%) is indicated
whom 3 the title of the compound, 30, 4.
Step 3. Tert-butyloxy-carbonyl-B-phenylalanyl-prolyl-b-arginine aldehyde hemisulfate.
6.4 g (10 mmol) of the protected tripeptide aldehyde (2) are dissolved in a mixture of 50 ml of water, 50 ml of tetrahydrofuran and 10 ml of 1N. sulfuric acid, then in the presence of 1 g of 10%. The solution is heated to 50 ° C, heated for 15 minutes at 50 ° C, then diluted with 25 ml of ice water and at: cooling the ice with water using solid calcium hydroxide (necessary about 1.6 g) set the pH to 6.5. The precipitated calcium sulphate is filtered and washed twice with 5 ml of water. The filtrate is extracted twice in 10m
 n-butanol, then concentrated under reduced pressure to approximately 30 ml, filtered, if necessary, finally lyophilized. 2.3 g (81%) of the substance given in s are obtained
palladium on active carbon in the skull of a product that contains
catalyst is hydrogenated, the reaction is followed by
Behind
using
thin-layer chromatography (R "- tripeptide-aldehyde, which is dense in its guanine group, is 0.95-1.0 and RI - free tripeptide-aldehyde is 0.45-0.54).

the catalyst is filtered off, washed with 30 ml of 50% aqueous tetrahydrofuran, then the filtrate is concentrated under reduced pressure to a volume of about 60 ml. The residue is extracted four times with 40 ml of butanol. If the aqueous phase contains the title product (Rf 0.45-0.54), 5 ml of tetrahydrofuran are added and it is extracted three times with 40 ml of n-butanol, the n-butanol phases are combined and evaporated to dryness under reduced pressure. After evaporation, the residue is triturated with a 1: 1 mixture of diethyl ether-diisopropyl ether, filtered and washed with the indicated mixture, then dried in a vacuum desiccator. 4.4 g (80%) of the title product are obtained. , 45-0,54.
 ± 10 (, in water).
Calculated,%: C 54.43; H 7.13; N 15.23; S0 8.71.
C2, (pyN, 0.5HvjS04 (551.64)
Found,%: C 54.5; H 7.3; . N 15.2; SO + 8.7.
PRI mme R 2. Preparation of D-phenyl-alanyl-b-prolyl-b-arginine deptl sulfate.
2.85 g (5 mmol) of tert-butyloxy-carbonyl-B-phenylalanyl-b-prolyl-K - carboxy-b-argininealdehyde is dissolved in 5 ml of water, with stirring
; 5 ml of 10 N are added. sulfuric acid.
The solution is heated to 50 ° C, heated at 50 ° C for 15 minutes, then diluted with 25 ml of ice water and at: cooling the ice with water with solid calcium hydroxide (approximately 1.6 g) is adjusted to pH 6, five. The precipitated calcium sulphate is filtered and washed twice with 5 ml of water. The filtrate is extracted twice with 10 ml.
n-butanol, then concentrated under reduced pressure to approximately a volume of 30 ml, if necessary, filtered, finally lyophilized. This gives 2.3 g (81%) of the product indicated in the preparation, which contains
4% calcium sulphate. , 35-0,40i tot3 117 ° t 1 (, in water). The original substance is obtained as follows.
55 6.4 g (10 mmol) of protected tripeptiddehyde (n zimmer 1, stage 2) are hydrogenated in 100 ml of 75% aqueous ethanol and in the presence of 1 g of 10%
palladium on active carbon as a catalyst. The course of the reaction is monitored by thin layer chromatography (Rf is the value of protected tripetidealdehyde and N-carboxy derivative is 0.90-0.95 and 0.45-0.55, respectively). After completion of the reaction, the catalyst is filtered off, washed with 30 ml of water, then the filtrate is concentrated under reduced pressure to a volume of 30-40 ml. The residue was diluted with 100 ml of water, extracted twice with 20 ml of methylene chloride and diophilized. Obtain 5.1 g (85%) of the title product. Er.0.45-), 0.55.
 Amino acid analysis; , 965 Pro - 1 (calculated on the basis) t B-phenyl-d obtained under the conditions of example 2 .. amino-methane-hydrochloride-salt on an acidic-alanyl-b-prolyl-b-arginine aldehyde sulfate has the composition CjoHjpjN 3H-. ., 2 CaS04 (mol. Mass 565.85).
Calculated,%: C 42.45; H 6.77; N 14.85; S04 21.13; Ca 1; 43; Hjo 9.55.,
Found,%: C 42.30; H 6.85; N 14.80; 80 20.90; Ca 1.35; H-Go 9.70.
PRI me R 3. B-phenylalanil-b-prolyl-b-arginine aldehyde sulfate.
The process is carried out under the conditions described in Example 1 with the difference that 2.74 g (5 mmol) of tert-butyloxycarbonyl-b-prolyl-b-arginine aldehyde; lusulphate is dissolved in 10 ml of 5N. sulfuric acid, the solution is stirred at 60 ° C for 10 minutes. The creeping product is identical to the product obtained in Example 1.
EXAMPLE 4. B-Phenyl nsh1-b-prolch-1-b-arginine aldehyde sulfate.
Proceed according to example 2 with that. only the difference that the solution containing 5 ml 12 n. sulfuric acid, stirred at 40 ° C for 20 minutes.
Example 5: Preparation of a pharmaceutical preparation.
The preparation in two ampoules, which is suitable for 6-12 hours infusion, is prepared as follows: 420-840 mg of B-phenylalanil-b-prolyl-b-argininaldehyde sulfate as a biologically active substance and 40-80 mg of human albumin are lyophilized together. The contents of the freeze-dried ampoule in this way are dissolved in 100 to 200 ml sterile, not containing
25
3
one (pH 7.2) that contains a peptide solution; 0.1 ml VS standard human thrombin (NIH. Maryland, USA), 10 units / ml solution.
The clotting time of the non-peptide system is 15, as determined by a Schnither-CroSS coagulmeter. The activity of the tripeptide aldehyde salt is estimated as 100, if
for a final concentration of the reaction mixture of 3.5x10 M (in the case of Tripeptide aldehyde sulfate 0.175 µg / ml of the reaction mixture), a 5-fold relative blood coagulation time was reached.
The results of the research are presented in Table 1. It follows that while the initial activity of the corresponding hydrochloride in the physiological saline solution begins to fall after 5 days, the activity of acetate, citrate, tartrate, and tosylate begins to fall already after a few days (L-carboxyl derivative of tripeptide aldehyde also possesses similar properties), B-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate retains its anti-thrombin activity after 90 days.
During prolonged (prolonged) stability studies, it turned out that B-phenylalanil-L-prolyl-L-arginine aldehyde sulfate, even after 180 days in the aqueous solution, is still stable and in a solid state after 6 May
. loses its activity.
Antithrombin activity is equal to 100 if peptide aldehyde in the final concentration of the reaction mixture is 3.5
40
50
pyrogen, isotonic saline solution.
It was found that the stability of various salts of B-phenylalanil-L-prolyl-L-arginine aldehyde in an aqueous solution, for example, in physiological saline solution, is very different. In our studies, the peptides are dissolved at a concentration of 10 mg / ml and the change in the antithrombin activity of the solutes. observed within 180 days. The solutions are stored at 5 ° C. The activity values are set in a system which consists of the following components: 0.2 ml of 0.5% cattle fibrinogen in a 0.9% solution of salt; 0.1 ml Tris (hydroxymethyl) buffer
amino methane hydrochloride salt to sour
one (pH 7.2) that contains a peptide solution; 0.1 ml VS standard human thrombin (NIH. Maryland, USA), 10 units / ml solution.
The clotting time of the non-peptide system is 15, as determined by a Schnither-CroSS coagulmeter. The activity of the tripeptide aldehyde salt is estimated as 100, if
The final concentration of the reaction mixture was 3.5x10 M (in the case of Tripeptide aldehyde sulfate 0.175 µg / ml of the reaction mixture), a 5-fold relative blood coagulation time was reached.
The results of the research are presented in Table 1. It follows that while the initial activity of the corresponding hydrochloride in the physiological saline solution begins to fall after 5 days, the activity of acetate, citrate, tartrate, and tosylate begins to fall already after a few days (L-carboxy is a derivative of tripeptide aldehyde also possesses similar properties), B-phenylalanyl-L-prolyl-L-arginine aldehyde sulfate retains its anti-thrombin activity after 90 days.
During prolonged (prolonged) stability studies, it turned out that B-phenylalanil-L-prolyl-L-arginine aldehyde sulfate, even after 180 days in the aqueous solution, is still stable and in a solid state after 6 May
loses its activity.
Antithrombin activity is equal to 100 if peptide aldehyde in the final concentration of the reaction mixture is 3.5
 causes a fivefold relative clotting time.
Similar to acetate, the antithrombin activity of the corresponding citrate, tartrate and tosylate is altered.
The antithrombin activity of the tripeptide aldehyde salts, as well as the carbamic acid derivative, was also tested on human plasma, which better meets the biological conditions in the following system: 0.2 ml of human citrate plasma} 0.1 ml of tri (oxymethyl) -amino-methane-hydrochloride- hydrochloric acid (, 2), which also contains a peptide solution; 0.1 ml VS standard human thrombin (N1H, Bethesda, Maryland, USA), 10 units / ml solution.
The blood coagulation time of the system was determined without a peptide at 15 with a Schnither-Gross coaguometer.
From the data of Table 2, it can be seen that the amount of peptide required for lengthening the time of the control) blood coagulation in the case of acetate and chlorohydrate salts depends on the loadings and the multiplicity also in the case of
15
acetate toxicity, as well as data on the toxicity of the carboxylic acid derivative. B Table 4 shows the acute toxicity values, in the case of tripeptide aldehyde sulfate, in the case of mice, a value of more than 2 g / kg is given.
Due to the low toxicity and high Q-activity of B-phenylalanil-L-proyl-b-arginine aldehyde sulfate, the relationship between the therapeutic and harmful drugs I / is much preferable to that of the other tripept aldehyde.
On the basis of studies on intravenous infusion of dogs with a view, but that the dose of intravenous exposure to a person is 1-2 mg / kg /

权利要求:
Claims (1)
[1]
The tests carried out showed that B-phenylalanil-L-prolyl-L-arginine aldehyde sulfate, obtained under the conditions of the proposed method, has a low toxicity, has high antithrombogenic activity, which is preserved for a long time during storage of the compound in aqueous plants. Formula from. bratis
The method of obtaining b-phenylalanil
20
SI,
, 01J.
40
iHjS04 HDPhe-b-Pro -NHCK
is clear
 Is distinguished
compound of formula
 sn,
 one
all - - f th - n - CH SNO
Yi
NH-C
HN
carbamic acid is y. Prosh-b-arginine aldehyde sulfate. military quantity amount of tripep-formula. aldehyde sulfate.,
The result of research in vivo derived tripeptidaldehyde presented in table 3. The antithrombin effect of O-phenylalanil-b-prolyl-b-arginine aldehyde sulfate in vivo is also very large. When administered intravenously and subcutaneously, it achieves the effect generally used in therapy.
№12
by that
sn, ta
nti
KN} 6.SH, S0
heparin, compared with heparin, even a positive effect (plus-effect) is achieved. While heparin is orally inactive with tripeptidaldehyde sulphate at an oral dose of 25 mg / kg, it is possible to achieve a therapeutic effect (using carbamic acid — only at a dose of 50 mg / kg).
The data on the toxicity of B-phenylalanyl-b-prolyl-b-arginine aldehyde sul - fate put it to it, than this
five
acetate toxicity, as well as data on the toxicity of the derivative of new carboxylic acids. B of Table 4 shows the values of acute toxicity, which in the case of tripeptidaldehyde sulfate in the case of mice, give a value of more than 2 g / kg.
Due to the low toxicity and high activity of B-phenylalanyl-b-prolyl-b-arginine dehydrate sulfate, the ratio between the therapeutic and harmful dosage I / is much more preferable than that of the other tripeptide aldehyde.
Based on studies on intravenous infusion of dogs, it is shown that the dose of intravenous infusion to humans is 1-2 mg / kg / h.
The tests carried out showed that B-phenylalanil-L-prolyl-L-arg - ninaldehyde sulfate, obtained under the conditions of the proposed method, is a compound with low toxicity, has a high antithrombogenic activity, which remains for a long time during storage of the compound in aqueous solutions. Formula from. bratis
The method of obtaining b-phenylalanil-b-,
0
SI,
, 01J.
0
iHjS04 HDPhe-b-Pro -NHCK
is clear
 Is distinguished
compound of formula
 sn,
 one
all - - f th - n - CH SNO
Yi
NH-C
HN
 UL-arginine aldehyde sulfate of the formula
five
№12
by that
sn, ta
nti
KN} 6.SH, S04
or formulas
t,
sn,
1st -1, -fpo-KH- SC
is clear
 deblocked by processing an equivalent amount of acid at 40-60 ° С
20 min, followed by neutralization of the solution and separation of the target product.
1442078
D-fen-pro-ar g-H.2CH, COOH D-fen-pro-arg-H.2 HC1
E) -phen-pro-arg- (cOOH) -N
D-phen-gfo-arg-N.
70-50 60-40 40-30 40-30 40-30 35-25 30-20 90-60. 90-60 80-50 70-40 60-40 50-30 40-30
100 80
60 50 30 25 20
100 100 100 100 100 100 100
The amount of the reaction mixture required to halve the blood coagulation time immediately after the peptide is dissolved.


0.020
0.065-0.140
0.060-0.130 0.105
 Values obtained with a commercial 132.2.2 U / mg, VS Ph XUP / Heparin.
Tabli
Note. The therapeutic effect is characterized by a 1.5-fold lengthening of the total clotting time.
10 Table I
60 50 30 25 20
Table 2
Relative activity
100
45 35-14
33-15 19
, 2 units / mg,
Table 3
0-fen-pro-arg-H, 9 B-fen-pro-arg (COOH) -H 0-fen-pro-arg-H.N,
heparin
Toxicity data for other forms of administration with an appropriate warranty are not given; With a one-hour intravenous infusion in the case of rabbits, the LD5 is 58 mg / kg.
TableA
38-960
1200
230 1800 2000
no literary data

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1442078A3|1988-11-30|Method of producing d-phenylalanyl-d-prolyl-l-arginine-aldehyde sulfate

---

SU1384203A3|1988-03-23|Method of producing peptidyl-arginine-aldehyde sulfates

---

EP0384362B1|1999-12-15|Glycinderivatives

---

RU2194037C2|2002-12-10|Nitrate inhibitor of ace

---

HU179734B|1982-12-28|Process for producing pharmaceutically effective new n-2 above-bracket-1,2,3,4-tetrahydro-8-quinolyl-bracket closed-sulfonyl-l-arginine-amides

---

US20210355163A1|2021-11-18|Compounds having triple activities of thrombolysis, antithrombotic and radical scavenging

---

HU205950B|1992-07-28|Process for producing new renin-inhibiting peptides and pharmaceutical compositions containing them

---

US4232007A|1980-11-04|Oral antilipemic agents

---

DE60004363T2|2004-06-24|FACTOR VIIA INHIBITORE

---

US3472832A|1969-10-14|Peptides related to caerulein

---

EP0177356A2|1986-04-09|Method for treatment of antidiuresis

---

CH623026A5|1981-05-15|

---

JP3162069B2|2001-04-25|Peptide derivative and therapeutic agent for thrombosis

---

JP2919870B2|1999-07-19|Liver damage inhibitor

---

US3475470A|1969-10-28|New amino acid ester complexes

---

US4339440A|1982-07-13|Enkephalin analogs and a process for the preparation thereof

---

KR910004428B1|1991-06-27|Process for the preparation of theophylline-7-acetic acid ester of d.l.-transsorbrenal

---

JP3250806B2|2002-01-28|N- | amino acids, processes for their preparation, their use in therapy and pharmaceutical compositions containing them

---

SU1048705A1|1985-03-30|Encephalin analogue possessing prolonged analgetic effect

---

JP2617700B2|1997-06-04|Polypeptide consisting of repeating structure of cell adhesion active core sequence

---

DE2636091C3|1981-01-22|Oral anti-inflammatory agent

---

SU1055105A1|1992-01-23|4-adamantoylamind-3-adamantoyl-6-methyl-2-ethyl-pyridine hydrochloride displaying psychostimulating activity

---

IL45776A|1977-12-30|Thiamphenicol derivatives their manufacture and pharmaceutical compositions containing them

---

EP0422055A1|1991-04-17|Novel ursodeoxycholic acid derivative

---

DE1518300B1|1972-02-03|A new hendekapeptide, its pharmaceutically acceptable salts and a process for its preparation

同族专利:

---

公开号 | 公开日

---

US4478745A|1984-10-23|

---

AT383352B|1987-06-25|

---

SE8200135L|1982-07-14|

---

DE3200812C2|1986-09-18|

---

GB2091270A|1982-07-28|

---

FI74024C|1987-12-10|

---

NL8200105A|1982-08-02|

---

BE891708A|1982-07-07|

---

PL133451B1|1985-06-29|

---

NO158021B|1988-03-21|

---

PT74268A|1982-02-01|

---

IT1210842B|1989-09-29|

---

IT8219074D0|1982-01-12|

---

DK9382A|1982-07-14|

---

DK151341C|1988-05-09|

---

DK151341B|1987-11-23|

---

AU544492B2|1985-05-30|

---

FR2497799A1|1982-07-16|

---

IL64761D0|1982-03-31|

---

FR2497799B1|1985-06-28|

---

PL234696A1|1982-09-13|

---

DE3200812A1|1982-08-12|

---

HU184368B|1984-08-28|

---

JPH0251920B2|1990-11-08|

---

PT74268B|1983-06-27|

---

CH649305A5|1985-05-15|

---

CA1182111A|1985-02-05|

---

JPS57181046A|1982-11-08|

---

MX156383A|1988-08-16|

---

ATA9782A|1986-11-15|

---

NO158021C|1988-06-29|

---

ES8301205A1|1982-11-16|

---

AU7944682A|1982-07-22|

---

FI820086L|1982-07-14|

---

GB2091270B|1984-08-22|

---

NO820083L|1982-07-14|

---

IL64761A|1985-01-31|

---

FI74024B|1987-08-31|

---

ES508637A0|1982-11-16|

---

US4399065A|1983-08-16|

---

SE453509B|1988-02-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3826793A|1968-10-21|1974-07-30|Bofors Ab|Anticoagulant peptides related to fibrino peptides|

---

HU169870B|1974-06-14|1977-02-28|

---

HU177098B|1979-01-04|1981-07-28|Gyogyszerkutato Intezet|Process for producing new peptidyl-n-carboxy-l-arginin-a|

---

HU184368B|1981-01-13|1984-08-28|Gyogyszerkutato Intezet|Process for preparing d-phenyl-alanyl-l-propyl-l-arginine-ald ehyde-shulphate|HU184368B|1981-01-13|1984-08-28|Gyogyszerkutato Intezet|Process for preparing d-phenyl-alanyl-l-propyl-l-arginine-ald ehyde-shulphate|

---

WO1984003044A1|1983-02-07|1984-08-16|Ferring Ab|Enzyme inhibitors|

---

DE3481913D1|1983-04-27|1990-05-17|Ici America Inc|PROLIN DERIVATIVES.|

---

HU192646B|1984-12-21|1987-06-29|Gyogyszerkutato Intezet|Process for preparing new n-alkyl-peptide aldehydes|

---

DE3505555A1|1985-02-18|1986-09-11|Behringwerke Ag, 3550 Marburg|NEW OLIGOPEPTIDYLARGININOL DERIVATIVES AND THEIR HOMOLOGOLOGY, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AND MEANS CONTAINING THEM|

---

DE3606480A1|1986-02-28|1987-09-03|Behringwerke Ag|OLIGOPEPTIDYLNITRILE DERIVATIVES, THESE CONTAINERS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE|

---

US5023236A|1988-04-07|1991-06-11|Corvas, Inc.|Factor VII/VIIA active site inhibitors|

---

US5332726A|1989-09-29|1994-07-26|Rhone-Poulenc Rorer Pharmaceuticals Inc.|Antithrombotic peptides and pseudopeptides|

---

US5064814A|1990-04-05|1991-11-12|Rhone-Poulenc Rorer Pharmaceuticals Inc.|Anti-thrombotic peptide and pseudopeptide derivatives|

---

GB2244994B|1990-06-12|1994-01-19|Richter Gedeon Vegyeszet|Improved process for the preparation of tripeptide aldehydes|

---

US5430023A|1990-09-28|1995-07-04|Eli Lilly And Company|Tripeptide antithrombotic agents|

---

CA2075154A1|1991-08-06|1993-02-07|Neelakantan Balasubramanian|Peptide aldehydes as antithrombotic agents|

---

US5416093A|1991-11-12|1995-05-16|Eli Lilly And Company|Antithrombotic agents|

---

US5252566A|1991-11-12|1993-10-12|Eli Lilly And Company|Antithrombotic agents|

---

US5250660A|1991-11-12|1993-10-05|Eli Lilly And Company|Peptide purification process|

---

JP3466614B2|1993-02-12|2003-11-17|コルバス・インターナショナル、インコーポレイテッド|Inhibitors of thrombosis|

---

JPH08501057A|1992-03-04|1996-02-06|ヂョヂセルクタトーインテーゼットカーエフテー|Novel anticoagulant factor peptide derivative, pharmaceutical composition containing the same, and method for producing the same|

---

US5576283A|1992-08-14|1996-11-19|The Procter & Gamble Company|Liquid detergents containing a peptide aldehyde|

---

US5582762A|1992-08-14|1996-12-10|The Procter & Gamble Company|Liquid detergents containing a peptide trifluoromethyl ketone|

---

ES2098483T3|1992-08-14|1997-05-01|Procter & Gamble|LIQUID DETERGENTS CONTAINING A PEPTIDIC ALDEHYDE.|

---

US5371072A|1992-10-16|1994-12-06|Corvas International, Inc.|Asp-Pro-Arg α-keto-amide enzyme inhibitors|

---

IL108031D0|1992-12-22|1994-04-12|Procter & Gamble|Difluoro pentapeptide derivatives and pharmaceutical compositions containing them|

---

US5484772A|1994-03-04|1996-01-16|Eli Lilly And Company|Antithrombotic agents|

---

US5439888A|1994-03-04|1995-08-08|Eli Lilly And Company|Antithrombotic agents|

---

US5602101A|1994-03-04|1997-02-11|Eli Lilly And Company|Antithrombotic agents|

---

US5436229A|1994-03-04|1995-07-25|Eli Lilly And Company|Bisulfite adducts of arginine aldehydes|

---

US5707966A|1994-03-04|1998-01-13|Eli Lilly And Company|Antithrombotic agents|

---

ZA951618B|1994-03-04|1996-08-27|Lilly Co Eli|Antithrombotic agents|

---

US5726159A|1994-03-04|1998-03-10|Eli Lilly And Company|Antithrombotic agents|

---

US5710130A|1995-02-27|1998-01-20|Eli Lilly And Company|Antithrombotic agents|

---

US5705487A|1994-03-04|1998-01-06|Eli Lilly And Company|Antithrombotic agents|

---

CA2143533A1|1994-03-04|1995-09-05|Kenneth D. Kurz|Antithrombotic agents|

---

US5914319A|1995-02-27|1999-06-22|Eli Lilly And Company|Antithrombotic agents|

---

US5885967A|1994-03-04|1999-03-23|Eli Lilly And Company|Antithrombotic agents|

---

US5488037A|1994-03-04|1996-01-30|Eli Lilly And Company|Antithrombotic agents|

---

US5932733A|1994-06-17|1999-08-03|Corvas International, Inc.|3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors|

---

US5656645A|1994-12-13|1997-08-12|Corvas International, Inc.|Aromatic heterocyclic derivatives as enzyme inhibitors|

---

US5658930A|1994-12-13|1997-08-19|Corvas International, Inc.|Aromatic heterocyclic derivatives as enzyme inhibitors|

---

US6245743B1|1996-06-05|2001-06-12|Cor Therapeutics, Inc.|Inhibitors of factor Xa|

---

US6022861A|1995-06-07|2000-02-08|Cor Therapeutics, Inc.|Ketoheterocyclic inhibitors of factor Xa|

---

US5919765A|1995-06-07|1999-07-06|Cor Therapeutics, Inc.|Inhibitors of factor XA|

---

US6069130A|1995-06-07|2000-05-30|Cor Therapeutics, Inc.|Ketoheterocyclic inhibitors of factor Xa|

---

US6046169A|1995-06-07|2000-04-04|Cor Therapeutics, Inc.|Inhibitors of factor XA|

---

US5721214A|1995-06-07|1998-02-24|Cor Therapeutics, Inc.|Inhibitors of factor Xa|

---

US6165966A|1996-09-24|2000-12-26|The Procter & Gamble Company|Liquid detergents containing proteolytic enzyme and protease inhibitors|

---

US6069232A|1995-10-02|2000-05-30|Hoechst Marion Roussel, Inc.|Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors|

---

DE19605039A1|1996-02-12|1997-08-14|Hoechst Ag|High yield and purity production of reversibly protected oligopeptide aldehyde|

---

US5739354A|1996-03-26|1998-04-14|Hoechst Marion Roussel, Inc.|Process for the preparation of N-methyl-D-phenylalanyl-N- 1- 3- amino!propyl!-3,3-difluoro-2-oxohexyl!-L-prolinamide|

---

IT1283467B1|1996-07-19|1998-04-21|Menarini Farma Ind|1,2 CYCLOALKANE DERIVATIVES REPLACED AS INHIBITORS OF THE THROMBIN, PROCEDURE FOR THEIR PREPARATION AND THEIR USE IN FORMULATIONS|

---

CN1113088C|1996-09-24|2003-07-02|普罗格特-甘布尔公司|Liquid detergents containing proteolytic enzyme and protease inhibitors|

---

WO1998013461A1|1996-09-24|1998-04-02|The Procter & Gamble Company|Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors|

---

US7090455B2|1998-11-13|2006-08-15|Pneutools, Incorporated|Stacked assembly of roofing caps|

---

US20110028397A1|2007-11-30|2011-02-03|Toezser Jozsef|Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders|

---

EP2343310A1|2010-01-08|2011-07-13|Novozymes A/S|Serine hydrolase formulation|

---

CN103649292B|2011-07-01|2017-11-28|诺维信公司|Stabilized subtilisin composition|

---

WO2016001319A1|2014-07-03|2016-01-07|Novozymes A/S|Improved stabilization of non-protease enzyme|

---

DE102015208655A1|2015-05-11|2016-11-17|Henkel Ag & Co. Kgaa|enzyme stabilizers|

---

DE102015210828A1|2015-06-12|2016-12-15|Henkel Ag & Co. Kgaa|Phosphate-free liquid dishwashing detergent|

---

DE102016209406A1|2016-05-31|2017-11-30|Henkel Ag & Co. Kgaa|Stabilized enzyme-containing detergents and cleaners|

---

DE102017219993A1|2017-11-09|2019-05-09|Henkel Ag & Co. Kgaa|Enzyme-containing detergent or cleaner|

---

DE102018129277A1|2018-11-21|2020-05-28|Henkel Ag & Co. Kgaa|Multi-component washing or cleaning agent containing a quinone oxidoreductase|

---

BR112021023457A2|2019-07-01|2022-01-25|Basf Se|Compound, use of the compound, composition, and, methods for preparing the composition and a compound|

---

EP3770237A1|2019-07-22|2021-01-27|Henkel AG & Co. KGaA|Washing and cleaning agents with improved enzyme stability|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

HU8170A|HU184368B|1981-01-13|1981-01-13|Process for preparing d-phenyl-alanyl-l-propyl-l-arginine-ald ehyde-shulphate|

---